Efficacy and Safety of Dalbavancin As Suppressive Therapy
Launched by HOSPICES CIVILS DE LYON · Mar 21, 2025
Trial Information
Current as of April 29, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness and safety of a medication called Dalbavancin (DAL) for treating acute or chronic infections. DAL is a type of antibiotic that works by killing bacteria, specifically targeting certain harmful types of bacteria known as Gram-positive bacteria, like Staphylococcus and Streptococcus. The trial is looking for adult participants (18 years and older) who have received DAL treatment for infections that have not improved with other treatments.
If you or a loved one decides to participate, you will be part of a study that aims to find out how well DAL works and whether it is safe to use. The trial is currently recruiting participants, and those who join will be closely monitored to track their health and any effects from the medication. It's important to know that participants must have previously received DAL for their infections and must not be younger than 18. This trial hopes to gather valuable information that could help improve treatment options for future patients with similar infections.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • \> 18 years
- • Patients received SAT with DAL for acute or chronic infections (defined as a long-standing infection due to a previously uneradicated pathogen, following unsuccessful antibiotic or surgical treatments) between July 2019 and December 2024
- • Patient who was informed and did not object to participating in the study
- Exclusion Criteria:
- • -\< 18 years
- • Subjects who received DAL not for SAT purposes
About Hospices Civils De Lyon
Hospices Civils de Lyon (HCL) is a leading public health institution in France, dedicated to providing high-quality healthcare and advancing medical research. With a rich history dating back to the 18th century, HCL encompasses multiple hospitals and offers a diverse range of services across various medical specialties. The institution is committed to fostering innovative clinical trials that aim to enhance patient care and improve therapeutic outcomes. By collaborating with academic and industry partners, HCL plays a pivotal role in the development of new treatments and the advancement of medical knowledge, ensuring that research efforts are aligned with the highest ethical standards and patient safety protocols.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
France, Lyon, France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported